Figure 4
From: Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer
Performance of the panel with three anti-TAA autoantibodies to detect ovarian cancer. (a) Receiver operating characteristic (ROC) curves of the panel (CFL1, EZR, CYPA) constructed by forward logistic regression method in validation cohort, (b) discovery cohort, (c) BD validation cohort (OC vs. BD), (d) BD validation cohort (OC vs. BD + NC), (e) Early stage (I–II) and (f) Late stage (III–IV). OC, Ovarian cancer; NC, normal control; BD, benign disease.
